Clinical Trial Update: Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a PSMA-targeted approach in HER2-negative, AR-positive metastatic breast cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Status: RECRUITING